Schrodinger SDGR Drug Discovery — Gross Profit
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Schrodinger in its filing.
Tagged under the XBRL concept us-gaap:GrossProfit.
The official record: Schrodinger’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Schrodinger's drug discovery — gross profit.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Schrodinger's drug discovery — gross profit?
- Schrodinger (SDGR) reported drug discovery — gross profit of $6.29M in Q1 2026.
- How has Schrodinger's drug discovery — gross profit changed year-over-year?
- Schrodinger's drug discovery — gross profit increased by 250.8% year-over-year, from -$4.17M to $6.29M.
- What is the long-term trend for Schrodinger's drug discovery — gross profit?
- Over 2 years (2021 to 2024), Schrodinger's drug discovery — gross profit has grown at a -26.6% compound annual growth rate (CAGR), from -$21.12M to -$11.38M.
- What does drug discovery — gross profit mean?
- This metric represents the gross profit generated specifically by the drug discovery business segment, calculated as segment revenue minus the direct costs associated with research, development, and collaboration activities. It serves as a key indicator of the profitability and operational efficiency of the company's internal and partnered drug discovery programs. Investors use this to evaluate the segment's ability to cover its direct costs and contribute to overall corporate profitability.